Share
Christopher Conway
BioDuro, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has appointed Christopher Conway, CEO of Bio X Cell, to its Board of Directors.
Backed by Advent International and the Bridgewest Group, BioDuro continues to enhance its leadership team to accelerate growth, expand global operations, and deliver innovative solutions for its biotech and pharmaceutical partners.
Mr. Conway brings over 25 years of industry experience spanning executive leadership, commercial operations, and strategic growth. He currently serves as CEO of Bio X Cell, a leading provider of functional antibody solutions specializing in large-scale RUO antibody manufacturing and services. Prior to Bio X Cell, he held executive roles at New York-based CDMO Curia (formerly AMRI), where he led the R&D business unit, and at Johnson & Johnson, where he held several commercial leadership positions.
In addition to his executive responsibilities, Mr. Conway contributes to industry leadership as a board member of the Drug, Chemical & Associated Technologies Association (DCAT) and previously served on the board of Viyash Life Sciences, a fully integrated pharmaceutical company specializing in niche formulations, APIs, and advanced intermediates.
His appointment underscores BioDuro’s commitment to strengthening governance and driving innovation to meet the evolving needs of the global life sciences industry.
